Carlton Hofferkamp & Jenks Wealth Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.24M | Sell |
8,845
-13
| -0.1% | -$2.8K | 0.72% | 30 |
|
|
2026
Q1 | $1.75M | Sell |
8,858
-906
| -9% | -$201K | 0.58% | 38 |
|
|
2025
Q4 | $2.23M | Sell |
9,764
-21
| -0.2% | -$4.78K | 0.75% | 33 |
|
|
2025
Q3 | $2.23M | Sell |
9,785
-226
| -2% | -$46K | 0.75% | 34 |
|
|
2025
Q2 | $1.9M | Sell |
10,011
-206
| -2% | -$38.3K | 0.69% | 34 |
|
|
2025
Q1 | $1.75M | Sell |
10,217
-116
| -1% | -$22.6K | 0.72% | 33 |
|
|
2024
Q4 | $1.98M | Sell |
10,333
-53
| -0.5% | -$9.74K | 0.73% | 32 |
|
|
2024
Q3 | $2.08M | Sell |
10,386
-205
| -2% | -$38.3K | 0.79% | 31 |
|
|
2024
Q2 | $1.98M | Buy |
10,591
+23
| +0.2% | +$3.81K | 0.77% | 33 |
|
|
2024
Q1 | $1.77M | Buy |
10,568
+43
| +0.4% | +$7.41K | 0.74% | 32 |
|
|
2023
Q4 | $1.73M | Hold |
10,525
| – | – | 0.72% | 33 |
|
|
2023
Q3 | $1.53M | Buy |
10,525
+75
| +0.7% | +$11K | 0.71% | 35 |
|
|
2023
Q2 | $1.54M | Buy |
10,450
+10
| +0.1% | +$1.47K | 0.68% | 33 |
|
|
2023
Q1 | $1.53M | Sell |
10,440
-333
| -3% | -$50.9K | 0.7% | 36 |
|
|
2022
Q4 | $1.58M | Sell |
10,773
-72
| -0.7% | -$11K | 0.69% | 36 |
|
|
2022
Q3 | $1.59M | Sell |
10,845
-65
| -0.6% | -$9.33K | 0.75% | 36 |
|
|
2022
Q2 | $1.67M | Buy |
10,910
+25
| +0.2% | +$3.82K | 0.77% | 34 |
|
|
2022
Q1 | $1.9M | Sell |
10,885
-274
| -2% | -$39.8K | 0.78% | 35 |
|
|
2021
Q4 | $1.49M | Sell |
11,159
-140
| -1% | -$16.5K | 0.63% | 44 |
|
|
2021
Q3 | $1.31M | Buy |
11,299
+471
| +4% | +$53.8K | 0.53% | 52 |
|
|
2021
Q2 | $1.27M | Sell |
10,828
-69
| -0.6% | -$7.77K | 0.55% | 50 |
|
|
2021
Q1 | $1.21M | Buy |
10,897
+875
| +9% | +$93.6K | 0.54% | 49 |
|
|
2020
Q4 | $1.12M | Sell |
10,022
-450
| -4% | -$43.2K | 0.55% | 50 |
|
|
2020
Q3 | $1.03M | Buy |
10,472
+1,967
| +23% | +$185K | 0.54% | 52 |
|
|
2020
Q2 | $825K | Buy |
8,505
+334
| +4% | +$29.4K | 0.47% | 56 |
|
|
2020
Q1 | $684K | Buy |
8,171
+1,566
| +24% | +$133K | 0.42% | 60 |
|
|
2019
Q4 | $555K | Buy |
6,605
+451
| +7% | +$37.4K | 0.31% | 71 |
|
|
2019
Q3 | $458K | Buy |
6,154
+1,500
| +32% | +$103K | 0.28% | 74 |
|
|
2019
Q2 | $318K | Buy |
4,654
+841
| +22% | +$66.1K | 0.19% | 80 |
|
|
2019
Q1 | $307K | Buy |
3,813
+786
| +26% | +$64.3K | 0.19% | 78 |
|
|
2018
Q4 | $279K | Buy |
+3,027
| New | +$266K | 0.2% | 76 |
|
Other funds holding ABBV
Carlton Hofferkamp & Jenks Wealth Management's ABBV Position: Q2 2026 in Review
Carlton Hofferkamp & Jenks Wealth Management reduced its AbbVie (ABBV) stake by 0.15% in Q2 2026, selling an estimated $2.8K and leaving 8,845 shares worth $2.24M. The position accounts for 0.72% of the portfolio, ranked #30.
Carlton Hofferkamp & Jenks Wealth Management first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Carlton Hofferkamp & Jenks Wealth Management held 8,845 shares of AbbVie worth $2.24M as of Q2 2026.
- Carlton Hofferkamp & Jenks Wealth Management sold 13 AbbVie shares in Q2 2026, an estimated $2.8K.
- AbbVie made up 0.72% of Carlton Hofferkamp & Jenks Wealth Management's portfolio in Q2 2026, its #30 holding.
- Carlton Hofferkamp & Jenks Wealth Management first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Carlton Hofferkamp & Jenks Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.